CN115944701A - Compound traditional Chinese medicine for treating ischemic stroke and preparation method thereof - Google Patents
Compound traditional Chinese medicine for treating ischemic stroke and preparation method thereof Download PDFInfo
- Publication number
- CN115944701A CN115944701A CN202310159672.6A CN202310159672A CN115944701A CN 115944701 A CN115944701 A CN 115944701A CN 202310159672 A CN202310159672 A CN 202310159672A CN 115944701 A CN115944701 A CN 115944701A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- raw materials
- ischemic stroke
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 45
- 208000032382 Ischaemic stroke Diseases 0.000 title claims abstract description 29
- 150000001875 compounds Chemical class 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 244000197580 Poria cocos Species 0.000 claims abstract description 31
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 31
- 241000304195 Salvia miltiorrhiza Species 0.000 claims abstract description 31
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims abstract description 31
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 30
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 30
- 235000006533 astragalus Nutrition 0.000 claims abstract description 28
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 27
- 241001522129 Pinellia Species 0.000 claims abstract description 27
- 241000382455 Angelica sinensis Species 0.000 claims abstract description 24
- 241000112528 Ligusticum striatum Species 0.000 claims abstract description 23
- 241000045403 Astragalus propinquus Species 0.000 claims abstract description 22
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 6
- 241001522232 Pinellia ternata Species 0.000 claims abstract description 4
- 239000002994 raw material Substances 0.000 claims description 33
- 238000000227 grinding Methods 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 7
- 241001061264 Astragalus Species 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 210000004233 talus Anatomy 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 229940042126 oral powder Drugs 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 241001106477 Paeoniaceae Species 0.000 claims 6
- 241000125175 Angelica Species 0.000 claims 1
- 239000008280 blood Substances 0.000 abstract description 53
- 210000004369 blood Anatomy 0.000 abstract description 50
- 230000000694 effects Effects 0.000 abstract description 35
- 244000170916 Paeonia officinalis Species 0.000 abstract description 21
- 230000017531 blood circulation Effects 0.000 abstract description 14
- 230000001737 promoting effect Effects 0.000 abstract description 14
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 12
- 208000026435 phlegm Diseases 0.000 abstract description 12
- 235000001188 Peltandra virginica Nutrition 0.000 abstract description 6
- 244000061520 Angelica archangelica Species 0.000 abstract description 5
- 241000913745 Spatholobus Species 0.000 abstract description 5
- 229940107666 astragalus root Drugs 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 5
- 230000017423 tissue regeneration Effects 0.000 abstract description 5
- 230000009286 beneficial effect Effects 0.000 abstract description 4
- 239000009636 Huang Qi Substances 0.000 abstract description 3
- 241000411851 herbal medicine Species 0.000 abstract description 3
- 244000164480 Curcuma aromatica Species 0.000 abstract description 2
- 235000003398 Curcuma aromatica Nutrition 0.000 abstract description 2
- 208000011580 syndromic disease Diseases 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 230000000903 blocking effect Effects 0.000 abstract 1
- 210000002216 heart Anatomy 0.000 description 15
- 230000007812 deficiency Effects 0.000 description 10
- 208000006011 Stroke Diseases 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 9
- 235000009508 confectionery Nutrition 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 6
- 230000003213 activating effect Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 206010008190 Cerebrovascular accident Diseases 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 4
- 240000007164 Salvia officinalis Species 0.000 description 4
- 208000026106 cerebrovascular disease Diseases 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 241000545744 Hirudinea Species 0.000 description 3
- 241000361919 Metaphire sieboldi Species 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 235000005412 red sage Nutrition 0.000 description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000008035 Back Pain Diseases 0.000 description 2
- 244000163122 Curcuma domestica Species 0.000 description 2
- 235000003392 Curcuma domestica Nutrition 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 235000003373 curcuma longa Nutrition 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 210000001156 gastric mucosa Anatomy 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 235000013976 turmeric Nutrition 0.000 description 2
- 206010047470 viral myocarditis Diseases 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- HARGZZNYNSYSGJ-UHFFFAOYSA-N 1,2 dihydrotanshinquinone Natural products C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)CO1 HARGZZNYNSYSGJ-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 235000013479 Amaranthus retroflexus Nutrition 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002482 Angiosclerosis Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 241000489492 Arisaema Species 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 240000005674 Ceanothus americanus Species 0.000 description 1
- 235000014224 Ceanothus americanus Nutrition 0.000 description 1
- 235000001904 Ceanothus herbaceus Nutrition 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 241000510667 Conioselinum Species 0.000 description 1
- 208000034657 Convalescence Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- GVKKJJOMQCNPGB-JTQLQIEISA-N Cryptotanshinone Chemical compound O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1[C@@H](C)CO2 GVKKJJOMQCNPGB-JTQLQIEISA-N 0.000 description 1
- GVKKJJOMQCNPGB-UHFFFAOYSA-N Cryptotanshinone Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)CO2 GVKKJJOMQCNPGB-UHFFFAOYSA-N 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- HARGZZNYNSYSGJ-JTQLQIEISA-N Dihydrotanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2[C@@H](C)CO1 HARGZZNYNSYSGJ-JTQLQIEISA-N 0.000 description 1
- 244000096857 Dioscorea batatas Species 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 244000286838 Eclipta prostrata Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 241000830535 Ligustrum lucidum Species 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 206010065951 Retrograde menstruation Diseases 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 240000006023 Trichosanthes kirilowii Species 0.000 description 1
- 235000009818 Trichosanthes kirilowii Nutrition 0.000 description 1
- 241000157352 Uncaria Species 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 208000019804 backache Diseases 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 1
- 229910001626 barium chloride Inorganic materials 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- KXNYCALHDXGJSF-UHFFFAOYSA-N dihydroisotanshinone I Natural products CC1=CC=CC2=C(C(C=3OCC(C=3C3=O)C)=O)C3=CC=C21 KXNYCALHDXGJSF-UHFFFAOYSA-N 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000002389 essential drug Substances 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000008695 pulmonary vasoconstriction Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001034 respiratory center Anatomy 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- KINGXFAMZNIVNL-SXQDSXCISA-N safflor yellow A Natural products OC[C@@H]1O[C@H]2[C@H](OC3=C2C(=O)C(=C(O)C=Cc4ccc(O)cc4)C(=O)[C@]3(O)[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)[C@@H](O)[C@H]1O KINGXFAMZNIVNL-SXQDSXCISA-N 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a compound traditional Chinese medicine for treating ischemic stroke and a preparation method thereof, wherein the compound traditional Chinese medicine comprises ligusticum wallichii, salvia miltiorrhiza, safflower, red paeony root, radix curcumae, astragalus mongholicus, angelica sinensis, caulis spatholobi, pinellia ternate and poria cocos, and the components are calculated according to the parts by mass: 10-20 parts of ligusticum wallichii, 8-12 parts of salvia miltiorrhiza, 4-6 parts of safflower, 7-9 parts of red paeony root, 6-12 parts of radix curcumae, 8-16 parts of astragalus mongholicus, 8-14 parts of angelica sinensis, 4-8 parts of caulis spatholobi, 5-11 parts of pinellia ternata and 5-11 parts of poria cocos; the invention has the beneficial effects that: the pinellia tuber, the curcuma aromatica and the tuckahoe have the effects of reducing phlegm, dredging collaterals and restoring consciousness by using; the use of the salvia miltiorrhiza, the red paeony root and the radix curcumae can cool blood and activate blood; the use of radix astragali, rhizoma Ligustici Chuanxiong, saviae Miltiorrhizae radix, radix Angelicae sinensis, caulis Spatholobi, and radix Curcumae can benefit qi and promote blood circulation; the astragalus root, the angelica and the spatholobus stem can tonify qi and enrich blood; the whole formula has the effects of promoting blood circulation, eliminating phlegm, removing blood stasis and promoting tissue regeneration; is suitable for patients with ischemic stroke and syndrome of phlegm-blood stasis blocking collaterals in traditional Chinese medicine; the invention has definite curative effect and simple prescription; adopts Chinese herbal medicine preparation, is safe in proportioning and has no toxic or side effect.
Description
Technical Field
The invention belongs to the technical field of compound traditional Chinese medicines, and particularly relates to a compound traditional Chinese medicine for treating ischemic stroke and a preparation method thereof.
Background
Apoplexy is a common disease and frequently-occurring disease in clinic, the apoplexy incidence rate shows a trend of rising year by year along with the change of diet and living habits and the aging of population, language, motor function and other obstacles can be left if the treatment is not timely and accurately and effectively carried out, the living and living quality of a patient is seriously affected, and certain family economic burden is brought; combining with the modern imaging results of CT/MRI and the like, the stroke is divided into ischemic stroke and hemorrhagic stroke, and the ischemic stroke accounts for the majority of the stroke.
Ischemic stroke is the most important cause of death and disability of the old, and seriously affects the health and life quality of the old; the incidence rate of cerebrovascular diseases in China is about 120-180/10 ten thousand population, more than 150 ten thousand new cases are generated every year, wherein more than 60 percent of cases are patients with cerebral infarction; in addition, in recent years, the incidence of cerebrovascular diseases is in a trend of slowly rising, ischemic stroke belongs to the category of stroke in traditional Chinese medicine, and through thousands of years of clinical practice, traditional Chinese medicine accumulates a lot of experiences in treating the cerebrovascular diseases; the recovery period of apoplexy refers to 2 weeks to half a year after the onset of the disease, which is the key period of recovery, if the intervention can be effectively carried out in time, the degree of apoplexy sequelae can be effectively reduced, and the recovery period has important significance for improving the life quality.
The patent application number is CN200710132360.7, which discloses a traditional Chinese medicine for treating ischemic stroke, the traditional Chinese medicine comprises 15 g of rhizoma gastrodiae, 12 g of uncaria, 15 g of ligusticum wallichii, 20 g of salvia miltiorrhiza, 10 g of angelica sinensis, 12 g of leech and earthworm respectively, 6 g of raw rhubarb, 12 g of trichosanthes kirilowii maxim, 10 g of arisaema cum bile, 15 g of fresh bamboo juice, 10 g of rhizoma polygonati, 9 g of liquorice, and 12 g of leech and earthworm respectively; the dosage materials in the prescription are all natural Chinese herbal medicines, and then the traditional processing method is added to prepare the traditional Chinese medicine composition, the materials are easy to obtain, the prescription and the preparation method are simple, and the cost of preparing the medicine is low.
The patent application number is 201510195511.8, which discloses a traditional Chinese medicine for treating ischemic stroke, which comprises the following components: 10-30 parts of radix rehmanniae, 12-20 parts of radix scrophulariae, 6-15 parts of radix asparagi, 6-15 parts of glossy privet fruit, 6-18 parts of eclipta alba, 6-15 parts of radix salviae miltiorrhizae, 6-12 parts of cortex moutan, 6-15 parts of radix paeoniae rubra, 6-15 parts of rhizoma acori graminei and 15-30 parts of raw malt, and has the advantages of good treatment effect and low recurrence after treatment.
The traditional Chinese medicine has better curative effect on the stroke convalescence; however, the existing Chinese patent medicine has fixed components and dosage, is not flexible enough to be applied by people, has unsatisfactory curative effect, and uses earthworm, leech and other worm medicinal materials, so that the patient has psychological worry when taking the medicine, and the rehabilitation of the patient is influenced.
Disclosure of Invention
The invention aims to provide a compound traditional Chinese medicine for treating ischemic stroke and a preparation method thereof, and the compound traditional Chinese medicine is used based on syndrome differentiation, has definite curative effect, simple prescription, flexible proportion, safety and reliability.
In order to achieve the purpose, the invention provides the following technical scheme: a compound traditional Chinese medicine for treating ischemic stroke comprises ligusticum wallichii, salvia miltiorrhiza, safflower, red paeony root, radix curcumae, astragalus mongholicus, angelica sinensis, caulis spatholobi, pinellia ternate and poria cocos, and comprises the following components in parts by mass: 10-20 parts of ligusticum wallichii, 8-12 parts of salvia miltiorrhiza, 4-6 parts of safflower, 7-9 parts of red paeony root, 6-12 parts of radix curcumae, 8-16 parts of astragalus mongholicus, 8-14 parts of angelica sinensis, 4-8 parts of caulis spatholobi, 5-11 parts of pinellia ternata and 5-11 parts of poria cocos.
As a preferred technical scheme of the invention, the raw materials are prepared from the following raw materials in parts by mass: 10 parts of ligusticum wallichii, 8 parts of salvia miltiorrhiza, 4 parts of safflower, 7 parts of red paeony root, 6 parts of radix curcumae, 8 parts of astragalus mongholicus, 8 parts of angelica sinensis, 4 parts of caulis spatholobi, 5 parts of pinellia ternate and 5 parts of poria cocos.
As a preferred technical scheme of the invention, the raw materials are prepared from the following raw materials in parts by mass: 15 parts of ligusticum wallichii, 10 parts of salvia miltiorrhiza, 5 parts of safflower, 8 parts of red paeony root, 9 parts of radix curcumae, 12 parts of astragalus mongholicus, 11 parts of angelica sinensis, 6 parts of caulis spatholobi, 8 parts of pinellia ternate and 8 parts of poria cocos.
As a preferred technical scheme of the invention, the raw materials are prepared from the following raw materials in parts by mass: 20 parts of ligusticum wallichii, 12 parts of salvia miltiorrhiza, 6 parts of safflower, 9 parts of red paeony root, 12 parts of radix curcumae, 16 parts of astragalus mongholicus, 14 parts of angelica sinensis, 8 parts of caulis spatholobi, 11 parts of pinellia ternate and 11 parts of poria cocos.
The invention also discloses a preparation method of the compound traditional Chinese medicine for treating ischemic stroke, which comprises the following steps:
the method comprises the following steps: preparing raw materials: the raw materials comprise 10-20 parts of hemlock parsley, 8-12 parts of salvia miltiorrhiza, 4-6 parts of safflower, 7-9 parts of red paeony root, 6-12 parts of turmeric root-tuber, 8-16 parts of astragalus, 8-14 parts of angelica, 4-8 parts of suberect spatholobus stem, 5-11 parts of pinellia tuber and 5-11 parts of tuckahoe;
step two: drying: drying the raw materials;
step three: superfine grinding: carrying out superfine grinding on the dried raw materials;
step four: uniformly mixing: mixing the superfine pulverized materials.
As a preferable technical scheme of the present invention, in the second step, the moisture content after drying is less than 6%.
In the third step, the mixture is subjected to superfine grinding and then is sieved by a 100-200-mesh sieve.
As a preferred technical scheme of the invention, the raw materials are uniformly mixed and then can be filled into a medicine bag or a capsule to obtain oral powder or a capsule.
Compared with the prior art, the invention has the beneficial effects that:
the pinellia ternate, the radix curcumae and the poria cocos have the effects of reducing phlegm, dredging collaterals and restoring consciousness; the use of the salvia miltiorrhiza, the red paeony root and the radix curcumae can cool blood and activate blood; the use of radix astragali, rhizoma Ligustici Chuanxiong, saviae Miltiorrhizae radix, radix Angelicae sinensis, caulis Spatholobi, and radix Curcumae can benefit qi, promote blood circulation, and dispel pathogenic wind; the astragalus root, the angelica and the spatholobus stem can tonify qi and enrich blood; the whole formula has the effects of promoting blood circulation, eliminating phlegm, removing blood stasis and promoting tissue regeneration; is suitable for patients with ischemic stroke, and is distinguished as wind phlegm stagnation type by traditional Chinese medicine; the invention has definite curative effect and simple prescription; adopts Chinese herbal medicine preparation, is safe in proportioning and has no toxic or side effect.
Drawings
FIG. 1 is a flow chart of the preparation method of the present invention.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
Referring to fig. 1, a first embodiment of the present invention provides a compound traditional Chinese medicine for treating ischemic stroke, which comprises ligusticum wallichii, salvia miltiorrhiza, safflower, red peony root, curcuma aromatica, astragalus, angelica sinensis, caulis spatholobi, pinellia ternate and poria cocos, and the components by mass portion are as follows: 10 parts of ligusticum wallichii, 8 parts of salvia miltiorrhiza, 4 parts of safflower, 7 parts of red paeony root, 6 parts of radix curcumae, 8 parts of astragalus mongholicus, 8 parts of angelica sinensis, 4 parts of caulis spatholobi, 5 parts of pinellia ternate and 5 parts of poria cocos.
Ligusticum wallichii: the rhizoma ligustici wallichii, pungent in flavor, capable of dissipating heat and dredging, has the effects of activating blood and removing stasis, and promoting qi circulation and relieving pain; can go up the vertex of the head and eyes, and has the functions of dispelling wind and relieving pain; animal experiments show that: rhizoma Ligustici Chuanxiong volatile oil can inhibit brain activity when applied in small amount, and has excitation effect on brain-extending respiratory center, motor center and spinal cord reflex center; the rhizoma ligustici wallichii has the function of enhancing blood circulation, and can accelerate the heart rate of animals, strengthen the myocardial contractility and dilate blood vessels; ligustrazine can inhibit pulmonary vasoconstriction caused by anoxia, and also has inhibitory effect on vasoconstriction caused by epinephrine or barium chloride;
red sage root: the red sage root is also named red ginseng, purple salvia root, red root and the like, is bitter in taste and slightly cold in nature, and enters heart and liver meridians, and has the effects of activating blood and removing stasis, stimulating the menstrual flow and relieving pain, clearing heart and relieving restlessness, cooling blood and eliminating carbuncle; the salvia miltiorrhiza bunge cathartic has the effects of bitter diarrhea, belongs to heart and liver meridians, mainly enters blood system, can promote blood circulation to remove blood stasis, remove blood stasis and promote tissue regeneration, and is a main medicine for treating frequent diseases of unsmooth blood circulation and blood stasis blockage; the red sage root enters heart and liver blood, has good passing effect, can activate blood and dissolve stasis, and is the essential drug for treating blood stasis; the salvia miltiorrhiza, which is cold in nature and enters heart meridian, has the functions of clearing heart fire, cooling blood, relieving restlessness and calming nerves, and can be used for treating hyperpyrexia, coma, dysphoria and insomnia caused by heat entering nutrient-blood and palpitation and insomnia caused by heart-blood deficiency; the salvia miltiorrhiza is cold in nature and enters the blood system, and is beneficial to clearing heat and cooling blood due to slight cold in nature, so the salvia miltiorrhiza can cool blood and activate blood, and can detoxify and eliminate rash; can dilate coronary artery, increase coronary blood flow, improve myocardial ischemia, infarction and heart function, regulate heart rhythm, dilate peripheral blood vessel, and improve microcirculation; the recovery period of red blood cells and hemoglobin is shortened, the reticulocytes are increased, and the tissue repair can be promoted; improving the activity of plasmin; prolonged bleeding and clotting time; inhibiting platelet aggregation and improving the rheological property of blood; contains cryptotanshinone and dihydrotanshinone, has inhibitory effect on in vitro staphylococcus, escherichia coli and Bacillus proteus, and Saviae Miltiorrhizae radix can inhibit blood lipid increase of high fat diet rabbit;
safflower: the part of the safflower used as the medicine is the dried flower of the safflower of the Compositae, the safflower is pungent in taste, warm in nature, and capable of entering the heart and liver meridians, has good effects of activating blood and dissolving stasis, is particularly suitable for people with blood stasis constitution and amenorrhea due to channel stagnation, and the safflower is pungent in property, capable of dispersing warm and dredging, and can be used for activating blood and dissolving stasis after entering the blood system; carthami flos has effects of relieving swelling and pain, and is suitable for various blood stasis diseases, such as thoracic obstruction, cardiodynia, costalgia, abdominal pain, subcutaneous cyanosis, and hemiplegia due to apoplexy; safflower also has the functions of promoting blood circulation and dredging collaterals so as to remove blood stasis and remove speckles; the safflower yellow contained in the safflower can expand peripheral blood vessels, inhibit platelet aggregation, enhance fibrinolysis and reduce the viscosity of whole blood, thereby playing a role in reducing blood pressure;
red peony root: radix Paeoniae Rubra is named as SHANYAO or CAOYAO, and has effects of nourishing yin, removing blood stasis, relieving pain, cooling blood, and relieving swelling;
turmeric root-tuber: the Yujin has the alias: yujin, yujing; nature and taste: pungent, bitter and cold in flavor, entering liver, heart and lung meridians; the pungent-flavor radix Curcumae can move energy and disperse, and can promote blood circulation and qi circulation; yu jin is pungent and bitter in flavor and can descend and purge, enter blood system of liver meridian and can cool blood, descend qi to stop bleeding, and is used for hematemesis, epistaxis and retrograde menstruation due to up-flow of qi and fire;
astragalus root: the astragalus root is sweet in taste and warm in nature; the astragalus membranaceus enters the lung channel and can tonify the qi of the body surface, is sweet and warm and enters the spleen channel, is a key medicine for tonifying spleen qi, enters the lung channel and can tonify the lung qi, can be used for treating symptoms such as cough weakness, shortness of breath, dyspnea, clear expectoration, low voice and the like caused by lung qi deficiency, can tonify the qi of the lung and the spleen, benefit the defense and strengthen the exterior to arrest sweating, can alleviate kidney lesion and has the function of diuresis, in addition, from the perspective of the traditional Chinese medicine, the spleen mainly transports and transforms water and dampness, and the spleen qi is deficient and fails to transport and transform, can tonify the spleen and tonify the body, can also promote diuresis to reduce edema, is one of important medicines for treating qi deficiency and edema, has the effect of nourishing blood, and is beneficial to enhancing the effect of hematopoiesis through the function of tonifying qi, so the astragalus membranaceus are also commonly used for treating the symptoms of blood deficiency and qi deficiency of both qi and blood deficiency; the astragalus has the cardiotonic effect, can increase the amplitude of cardiac contraction and increase the output, and has more obvious effect on poisoning or fatigue failure and heart; in addition, for the autoimmune reaction caused by the viral myocarditis, the astragalus can also inhibit the viral myocarditis by enhancing the immune function and has the function of promoting the induction of interferon; the astragalus has the effects of protecting the liver, enhancing the hematopoietic function and promoting the growth of white blood cells so as to enhance the immune function of a human body;
chinese angelica root: chinese angelica root, radix Angelicae sinensis is warm in nature, sweet and pungent in flavor; the angelica has strong blood replenishing effect, is called as a first blood replenishing medicine, is sweet and heavy in taste, can specially enrich blood, is suitable for various blood deficiency symptoms, has the functions of promoting blood circulation to remove blood stasis, warming and activating meridian, relieving pain and spasm, and relaxing bowel;
spatholobus stem: caulis Spatholobi is a Leguminosae plant with high medicinal value, mainly grows in forest, brush or valley forest, and has effects of promoting blood circulation, replenishing blood, regulating menstruation, relieving rigidity of muscles and activating collaterals; caulis Spatholobi has effects of dilating blood vessel, resisting blood platelet aggregation, promoting phosphorus metabolism, and can be used for treating angiosclerosis and lumbago and backache; treating aplastic anemia;
pinellia ternata: pinellia ternate is also called as pinellia ternate, is named as pinellia ternate, is used for three-step jumping, inscription and field conservation, has the effects of eliminating dampness and resolving phlegm, and is mainly used for treating phlegm-fluid dizziness and palpitation and wind-phlegm dizziness; now, pharmacological research also finds that the pinellia ternate can inhibit the activity of pepsin, protect gastric mucosa and promote the repair of the gastric mucosa;
tuckahoe, poria cocos: the tuckahoe is neutral in nature and sweet in taste, and enters heart, lung, spleen and kidney meridians, the tuckahoe is sweet and mild in taste, the sweet can tonify the body, the light can permeate the body, the medicine property is mild, the tuckahoe can eliminate pathogenic factors, strengthen body resistance and promote diuresis without damaging body resistance, is one of important medicinal materials in traditional Chinese medicines for promoting diuresis and reducing edema, and can be used for treating edema caused by various cold, heat, deficiency and excess and other reasons; poria has effects of invigorating heart and spleen, calming heart and tranquilizing mind, and can be used for treating deficiency of both heart and spleen, and deficiency of qi and blood; pachyman has effect of enhancing organism immunity, and can be administered to improve cell immunity of the elderly.
The pinellia ternate, the radix curcumae and the poria cocos have the effects of reducing phlegm, dredging collaterals and restoring consciousness;
the use of the salvia miltiorrhiza, the red paeony root and the radix curcumae can cool blood and activate blood;
the use of radix astragali, rhizoma Ligustici Chuanxiong, saviae Miltiorrhizae radix, radix Angelicae sinensis, caulis Spatholobi, and radix Curcumae can benefit qi, promote blood circulation, and dispel pathogenic wind;
the astragalus root, the angelica and the spatholobus stem can tonify qi and enrich blood;
the whole formula has the effects of promoting blood circulation, eliminating phlegm, removing blood stasis and promoting tissue regeneration;
a preparation method of a compound traditional Chinese medicine for treating ischemic stroke comprises the following steps:
the method comprises the following steps: preparing raw materials: the raw materials comprise 10 parts of ligusticum wallichii, 8 parts of salvia miltiorrhiza, 4 parts of safflower, 7 parts of red paeony root, 6 parts of radix curcumae, 8 parts of astragalus mongholicus, 8 parts of angelica sinensis, 4 parts of caulis spatholobi, 5 parts of pinellia ternate and 5 parts of poria cocos;
step two: drying: drying the raw materials, wherein the water content of the dried raw materials is less than 6%;
step three: superfine grinding: micronizing the dried raw materials, and sieving with 100 mesh sieve;
step four: uniformly mixing: mixing the superfine pulverized materials, and packaging into medicinal bag or capsule to obtain oral powder.
Example 2
Referring to fig. 1, a second embodiment of the present invention is shown, which is based on the previous embodiment except that:
a compound traditional Chinese medicine for treating ischemic stroke comprises ligusticum wallichii, salvia miltiorrhiza, safflower, red paeony root, radix curcumae, astragalus mongholicus, angelica sinensis, caulis spatholobi, pinellia ternate and poria cocos, and the components are calculated according to parts by mass: 15 parts of ligusticum wallichii, 10 parts of salvia miltiorrhiza, 5 parts of safflower, 8 parts of red paeony root, 9 parts of radix curcumae, 12 parts of astragalus mongholicus, 11 parts of angelica sinensis, 6 parts of caulis spatholobi, 8 parts of pinellia ternate and 8 parts of poria cocos.
Preparing raw materials: the raw materials comprise 15 parts of ligusticum wallichii, 10 parts of salvia miltiorrhiza, 5 parts of safflower, 8 parts of red paeony root, 9 parts of radix curcumae, 12 parts of astragalus mongholicus, 11 parts of angelica sinensis, 6 parts of caulis spatholobi, 8 parts of pinellia ternate and 8 parts of poria cocos;
the dried raw materials are subjected to superfine grinding and then are sieved by a 150-mesh sieve.
To obtain capsule.
Example 3
Referring to fig. 1, a third embodiment of the present invention is shown, which is based on the previous embodiment except that:
a compound traditional Chinese medicine for treating ischemic stroke comprises ligusticum wallichii, salvia miltiorrhiza, safflower, red paeony root, radix curcumae, astragalus mongholicus, angelica sinensis, caulis spatholobi, pinellia ternate and poria cocos, and the components are calculated according to parts by mass: 20 parts of ligusticum wallichii, 12 parts of salvia miltiorrhiza, 6 parts of safflower, 9 parts of red paeony root, 12 parts of radix curcumae, 16 parts of astragalus mongholicus, 14 parts of angelica sinensis, 8 parts of caulis spatholobi, 11 parts of pinellia ternate and 11 parts of poria cocos.
Preparing raw materials: the raw materials comprise 20 parts of ligusticum wallichii, 12 parts of salvia miltiorrhiza, 6 parts of safflower, 9 parts of red paeony root, 12 parts of radix curcumae, 16 parts of astragalus mongholicus, 14 parts of angelica sinensis, 8 parts of caulis spatholobi, 11 parts of pinellia ternate and 11 parts of poria cocos;
the dried raw materials are subjected to superfine grinding and sieved by a 200-mesh sieve after superfine grinding.
To obtain oral powder.
The taking method comprises the following steps: the medicine is taken 3 g each time in the morning and evening for 20-40 days.
200 cases of patients with ischemic stroke are treated by using the compound traditional Chinese medicine, wherein 60 cases account for 30% of patients in one course of treatment; 70 cases are cured in two treatment courses, accounting for 35 percent; 40 cases are cured by more than three courses of treatment, accounting for 20 percent; the disease condition is controlled to be 30 cases, accounting for 15 percent; the traditional Chinese medicine composition has a remarkable curative effect on wind phlegm stasis type in the ischemic stroke recovery period.
Although embodiments of the present invention have been shown and described, with particular reference to the foregoing detailed description, it will be appreciated by those skilled in the art that changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
Claims (8)
1. A compound traditional Chinese medicine for treating ischemic stroke is characterized in that: comprises rhizoma ligustici wallichii, salvia miltiorrhiza, safflower, red paeony root, radix curcumae, astragalus, angelica, caulis spatholobi, pinellia ternate and poria cocos, and the components are calculated according to the parts by mass: 10-20 parts of ligusticum wallichii, 8-12 parts of salvia miltiorrhiza, 4-6 parts of safflower, 7-9 parts of red paeony root, 6-12 parts of radix curcumae, 8-16 parts of astragalus mongholicus, 8-14 parts of angelica sinensis, 4-8 parts of caulis spatholobi, 5-11 parts of pinellia ternata and 5-11 parts of poria cocos.
2. The compound traditional Chinese medicine for treating ischemic stroke according to claim 1, which is characterized in that: the raw materials are prepared from the following raw materials in parts by mass: 10 parts of ligusticum wallichii, 8 parts of salvia miltiorrhiza, 4 parts of safflower, 7 parts of red paeony root, 6 parts of radix curcumae, 8 parts of astragalus mongholicus, 8 parts of angelica sinensis, 4 parts of caulis spatholobi, 5 parts of pinellia ternate and 5 parts of poria cocos.
3. The compound traditional Chinese medicine for treating ischemic stroke according to claim 1, which is characterized in that: the raw materials are prepared from the following raw materials in parts by mass: 15 parts of ligusticum wallichii, 10 parts of salvia miltiorrhiza, 5 parts of safflower, 8 parts of red paeony root, 9 parts of radix curcumae, 12 parts of astragalus mongholicus, 11 parts of angelica sinensis, 6 parts of caulis spatholobi, 8 parts of pinellia ternate and 8 parts of poria cocos.
4. The compound traditional Chinese medicine for treating ischemic stroke according to claim 1, which is characterized in that: the raw materials are prepared from the following raw materials in parts by mass: 20 parts of ligusticum wallichii, 12 parts of salvia miltiorrhiza, 6 parts of safflower, 9 parts of red paeony root, 12 parts of radix curcumae, 16 parts of astragalus mongholicus, 14 parts of angelica sinensis, 8 parts of caulis spatholobi, 11 parts of pinellia ternate and 11 parts of poria cocos.
5. The preparation method of the compound traditional Chinese medicine for treating ischemic stroke according to any one of claims 1 to 4, characterized in that: the preparation method comprises the following steps:
the method comprises the following steps: preparing raw materials: the raw materials comprise 10-20 parts of ligusticum wallichii, 8-12 parts of salvia miltiorrhiza, 4-6 parts of safflower, 7-9 parts of red paeony root, 6-12 parts of radix curcumae, 8-16 parts of astragalus mongholicus, 8-14 parts of angelica sinensis, 4-8 parts of caulis spatholobi, 5-11 parts of pinellia ternate and 5-11 parts of poria cocos;
step two: and (3) drying: drying the raw materials;
step three: superfine grinding: carrying out superfine grinding on the dried raw materials;
step four: uniformly mixing: mixing the superfine pulverized materials.
6. The preparation method of the compound traditional Chinese medicine for treating ischemic stroke according to claim 5, characterized in that: in the second step, the water content after drying is less than 6%.
7. The preparation method of the compound traditional Chinese medicine for treating ischemic stroke according to claim 5, which is characterized in that: in the third step, the mixture is sieved by a sieve of 100 to 200 meshes after being crushed in an ultrafine way.
8. The preparation method of the compound traditional Chinese medicine for treating ischemic stroke according to claim 5, which is characterized in that: the raw materials are mixed evenly and then can be filled into medicine bags or capsules to obtain oral powder or capsules.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310159672.6A CN115944701A (en) | 2023-02-20 | 2023-02-20 | Compound traditional Chinese medicine for treating ischemic stroke and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310159672.6A CN115944701A (en) | 2023-02-20 | 2023-02-20 | Compound traditional Chinese medicine for treating ischemic stroke and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115944701A true CN115944701A (en) | 2023-04-11 |
Family
ID=87286231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310159672.6A Pending CN115944701A (en) | 2023-02-20 | 2023-02-20 | Compound traditional Chinese medicine for treating ischemic stroke and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115944701A (en) |
-
2023
- 2023-02-20 CN CN202310159672.6A patent/CN115944701A/en active Pending
Non-Patent Citations (1)
| Title |
|---|
| 郑敬肖等: "中西医结合治疗缺血性中风60例疗效观察", 河北中医, vol. 33, no. 04, pages 566 - 567 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104491759B (en) | A kind of Chinese medicine composition for treating antimigraine and preparation method thereof | |
| CN102526674A (en) | Medicine for treating bronchitis and bronchial asthma suffered by children aging from three to seven | |
| CN105833206B (en) | Traditional Chinese medicine composition for conditioning sub-health and preparation method thereof | |
| CN102552773A (en) | Drug for treating bronchitis and bronchial asthma of 7-15 year old children | |
| CN103721236A (en) | Traditional Chinese medicinal composition for treating gastropathy | |
| CN103463586A (en) | Traditional Chinese medicine composition for treating restless legs syndrome | |
| CN103223118A (en) | Traditional Chinese medicine composition for treating facial paralysis | |
| CN103301356A (en) | Preparation method of enema for chronic renal failure | |
| CN103301355A (en) | Preparation method of chronic renal failure colon dialysate | |
| CN103330868A (en) | Intestinal tract replenishing liquid for chronic renal failure | |
| CN106668508A (en) | Traditional Chinese medicine prescription for treating neurasthenia | |
| CN103550717A (en) | Traditional Chinese medicine for treating pneumonia | |
| CN105902793A (en) | Traditional Chinese medicine for treatment of coronary heart disease | |
| CN105831751B (en) | Traditional Chinese medicine health-care composition for tonifying qi and strengthening brain, preparation method and use method thereof | |
| CN104225507A (en) | Chinese medicine for treating limb paralysis and pain caused by cerebral hemorrhage | |
| CN103800582A (en) | Traditional Chinese medicine preparation for treating tinnitus | |
| CN115944701A (en) | Compound traditional Chinese medicine for treating ischemic stroke and preparation method thereof | |
| CN103341095B (en) | Clysis liquid used for chronic renal failure | |
| CN105963505A (en) | Traditional Chinese medicinal foot bath powder capable of treating insomnia | |
| CN110201056A (en) | A kind of Chinese medicine composition and its preparation, preparation method and application | |
| CN104958677A (en) | Traditional Chinese medicine preparation for treating membranous nephropathy and preparation method of traditional Chinese medicine preparation | |
| CN104606600A (en) | Traditional Chinese medicine composition for treating interstitial lung disease and preparation method of composition | |
| CN104524535B (en) | It is a kind of to treat Chinese medicine composition of chronic cor pulmonale and preparation method thereof | |
| CN104740405B (en) | A kind of Chinese medicine preparation and preparation method for treating anaphylactoid purpura renal damage | |
| CN104547973A (en) | Health traditional Chinese medicine for treating chest obstruction and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20230411 |